Candesartan
- Generic Name
- Candesartan
- Brand Names
- Atacand, Atacand Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H20N6O3
- CAS Number
- 139481-59-7
- Unique Ingredient Identifier
- S8Q36MD2XX
- Background
Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is available as a prodrug in the form of candesartan cilexetil.
- Indication
May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction an...
- Associated Conditions
- Hypertension, NYHA Functional Class II-IV Heart Failure
- Associated Therapies
- -
Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Angiotensin Converting Enzyme 2 (ACE2): Diabetic Patients Treated With Antihypertensive Drugs
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-02-23
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 20
- Registration Number
- NCT00192803
- Locations
- 🇮🇱
Internal Ward "A", Rambam Medical Center, Haifa, Israel
Prophylactic Treatment of Episodic Cluster Headache
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2013-04-23
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 40
- Registration Number
- NCT00184587
- Locations
- 🇳🇴
Norwegian National Headache Centre St.Olavs Hospital, Trondheim, Norway
Danish Hypertension Prevention Project - DHYPP
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2014-11-26
- Lead Sponsor
- Karin Skov
- Target Recruit Count
- 100
- Registration Number
- NCT00150631
- Locations
- 🇩🇰
Karin Skov, Aarhus, Denmark
Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2013-04-18
- Lead Sponsor
- Kumamoto University
- Target Recruit Count
- 1119
- Registration Number
- NCT00139386
- Locations
- 🇯🇵
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Candesartan in the Prevention of Relapsing Atrial Fibrillation
- Conditions
- First Posted Date
- 2005-08-17
- Last Posted Date
- 2007-01-04
- Lead Sponsor
- Asker & Baerum Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT00130975
- Locations
- 🇳🇴
Ulleval University Hospital, Oslo, Norway
🇳🇴Asker & Baerum Hospital, Rud, Norway
Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients
- Conditions
- First Posted Date
- 2005-08-01
- Last Posted Date
- 2005-08-10
- Lead Sponsor
- The Japanese Society of Hypertension
- Target Recruit Count
- 3200
- Registration Number
- NCT00125463
- Locations
- 🇯🇵
Kyoto University, Kyoto, Yoshidakonoe-cho, Sakyo-ku, Kyoto, Japan
Scandinavian Candesartan Acute Stroke Trial (SCAST)
- First Posted Date
- 2005-07-14
- Last Posted Date
- 2011-07-01
- Lead Sponsor
- Ullevaal University Hospital
- Target Recruit Count
- 2500
- Registration Number
- NCT00120003
- Locations
- 🇳🇴
Ullevaal University Hospital, Oslo, Norway
Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)
- Conditions
- First Posted Date
- 2005-04-19
- Last Posted Date
- 2006-09-13
- Lead Sponsor
- City Hospitals Sunderland NHS Foundation Trust
- Target Recruit Count
- 50
- Registration Number
- NCT00108706
- Locations
- 🇬🇧
Sunderland Royal Hospital, Sunderland, Tyne and Wear, United Kingdom
Genetic Epidemiology of Responses to Antihypertensives
- Conditions
- Interventions
- First Posted Date
- 2000-05-26
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 1200
- Registration Number
- NCT00005520
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.